绿竹生物-B(02480)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02480 绿竹生物-B

午间休市 05-09 12:05:00

21.550

-0.050

-0.23%

最高21.550	最低21.550	成交量298.66万
今开21.550	昨收21.600	日振幅0.00%
总市值42.88亿	流通市值42.88亿	总股本1.99亿
成交额6,571万	换手率1.50%	流通股本1.99亿
市净率4.68	ROE-17.95%	每股收益-0.89
52周最高27.450	52周最低19.000	市盈率-24.10
股息0.00	股息收益率0.00	ROA-11.31%

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02480","market":"HK","secType":"STK","nameCN":"绿竹生物-B","latestPrice":21.55,"timestamp":1746763500006,"preClose":21.6,"halted":0,"volume":2986600,"delay":0,"floatShares":199000000,"shares":199000000,"eps":-0.8942689374941692,"marketStatus":"午间休市","change":-0.05,"latestTime":"05-09 12:05:00","open":21.55,"high":21.55,"low":21.55,"amount":65705110,"amplitude":0,"askPrice":21.55,"askSize":1600,"bidPrice":20.6,"bidSize":400,"shortable":3,"etf":0,"ttmEps":-0.8942689374941692,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1746766800000},"marketStatusCode":3,"adr":0,"listingDate":1683475200000,"exchange":"SEHK","adjPreClose":21.6,"openAndCloseTimeList":[[1746754200000,1746763200000],[1746766800000,1746777600000]],"volumeRatio":18.118575,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02480","defaultTab":"news","newsList":[{"id":"2533914702","title":"绿竹生物-B盘中异动 急速下挫5.68%报20.750港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2533914702","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533914702?lang=zh_cn&edition=full","pubTime":"2025-05-08 10:31","pubTimestamp":1746671484,"startTime":"0","endTime":"0","summary":"2025年05月08日早盘10时31分，绿竹生物-B股票出现波动，股价急速下挫5.68%。截至发稿，该股报20.750港元/股，成交量200股，换手率0.00%，振幅0.00%。资金方面，该股资金流入0港元，流出4150港元。绿竹生物-B股票所在的生物技术行业中，整体涨幅为0.06%。该公司还从事对外授权人类疫苗及治疗性生物制剂。其LZ901主要应用于预防年龄为50岁及以上成人水痘带状疱疹病毒引起的带状疱疹。对此，百克生物表示，主要系本报告期带状疱疹疫苗销量减少所致。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250508103125aa2c86c1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250508103125aa2c86c1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02480"],"gpt_icon":0},{"id":"2533616225","title":"核心带疱疫苗或在明年上市，能否将绿竹生物-B(02480)拖出“流动性陷阱”？","url":"https://stock-news.laohu8.com/highlight/detail?id=2533616225","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533616225?lang=zh_cn&edition=full","pubTime":"2025-05-07 09:29","pubTimestamp":1746581356,"startTime":"0","endTime":"0","summary":"对此，百克生物表示，主要系本报告期带状疱疹疫苗销量减少所致。然而，受到百克生物此次年报业绩表现打击最大的似乎并非百克本身，而是尚未实现产品收入且核心带疱疫苗即将上市的绿竹生物-B。今年一季度，国内疫苗行业上市公司似乎集体遭遇了“滑铁卢”。回到带疱疫苗，其实目前市场竞争环境良好，因为仅有百克生物的感维和GSK的Shingrix上市，如果绿竹生物的LZ901能够按预期的2026年上半年前后商业化，便可成为国内第三款带疱疫苗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1289981.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02480","159646","BK1161"],"gpt_icon":0},{"id":"2533542602","title":"绿竹生物-B盘中异动 股价大跌7.95%报20.250港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2533542602","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533542602?lang=zh_cn&edition=full","pubTime":"2025-05-06 09:48","pubTimestamp":1746496126,"startTime":"0","endTime":"0","summary":"2025年05月06日早盘09时48分，绿竹生物-B股票出现波动，股价大幅下跌7.95%。截至发稿，该股报20.250港元/股，成交量1200股，换手率0.00%，振幅0.00%。资金方面，该股资金流入0港元，流出2.43万港元。绿竹生物-B股票所在的生物技术行业中，整体涨幅为0.54%。其临床阶段在研产品包括重组带状疱疹疫苗LZ901,以及抗体注射产品K3和K193。其LZ901主要应用于预防年龄为50岁及以上成人水痘带状疱疹病毒引起的带状疱疹。该公司在中国国内市场和海外市场开展业务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050609484694ed618f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050609484694ed618f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02480","BK1161"],"gpt_icon":0},{"id":"2532481468","title":"绿竹生物-B(02480)5月2日斥资3971.33万港元回购175.92万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2532481468","media":"智通财经","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2532481468?lang=zh_cn&edition=full","pubTime":"2025-05-02 18:51","pubTimestamp":1746183090,"startTime":"0","endTime":"0","summary":"智通财经APP讯，绿竹生物-B(02480)发布公告，于2025年5月2日斥资3971.33万港元回购股份175.92万股，每股回购价格为21.95-23港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1289054.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02480","BK1161"],"gpt_icon":0},{"id":"2531772732","title":"绿竹生物-B股价重挫10.20% 市值跌4.51亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2531772732","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531772732?lang=zh_cn&edition=full","pubTime":"2025-04-30 14:15","pubTimestamp":1745993720,"startTime":"0","endTime":"0","summary":"2025年04月30日下午盘14时15分，绿竹生物-B股票出现波动，股价快速跳水10.20%。截至发稿，该股报22.000港元/股，成交量800股，换手率0.00%，振幅10.00%。资金方面，该股资金流入1.831万港元，流出0港元。绿竹生物-B股票所在的生物技术行业中，整体涨幅为1.70%。其临床阶段在研产品包括重组带状疱疹疫苗LZ901,以及抗体注射产品K3和K193。其LZ901主要应用于预防年龄为50岁及以上成人水痘带状疱疹病毒引起的带状疱疹。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025043014152094e88a81&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025043014152094e88a81&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02480","BK1161"],"gpt_icon":0},{"id":"2529177338","title":"绿竹生物-B：核心产品重组带状疱疹疫苗LZ901上市申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2529177338","media":"国信证券","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529177338?lang=zh_cn&edition=full","pubTime":"2025-04-21 00:00","pubTimestamp":1745164800,"startTime":"0","endTime":"0","summary":"投资建议：公司核心品种重组带状疱疹疫苗LZ901 采用创新抗原设计，诱导高水平体液及细胞免疫应答的同时，兼具较好的安全性；LZ901 已提交上市申请并获受理，预计将于2026H1 实现产品商业化，考虑到国内疫苗新产品一般需要3~6 个月进行省级招标准入，我们预计LZ901 将于2026H2 开始贡献收入增量。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250421112124a6c1c53f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250421112124a6c1c53f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02480","BK1161"],"gpt_icon":0},{"id":"2528794642","title":"绿竹生物：2024年亏损收窄32.5% 核心产品LZ901冲刺上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2528794642","media":"中国财富通","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2528794642?lang=zh_cn&edition=full","pubTime":"2025-04-17 18:19","pubTimestamp":1744885198,"startTime":"0","endTime":"0","summary":"报告期内，公司归母净利润亏损1.68亿元，但较上年同期的2.49亿元亏损已大幅收窄32.5%，亏损情况有所改善。业内人士指出，未来三年，随着LZ901上市和放量、HSV等其他疫苗进入临床以及更多管线的价值释放，公司有望实现从技术优势到商业价值的闭环验证。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://irb.cfbond.com/api/v1/detail.html?newsid=YmgxU56HoFI%3D","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02480"],"gpt_icon":0},{"id":"2527760249","title":"绿竹生物-B(02480)提名孔健为第五届董事会执行董事候选人","url":"https://stock-news.laohu8.com/highlight/detail?id=2527760249","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527760249?lang=zh_cn&edition=full","pubTime":"2025-04-16 21:47","pubTimestamp":1744811272,"startTime":"0","endTime":"0","summary":"智通财经APP讯，绿竹生物-B(02480)发布公告，经考虑董事会提名委员会的推荐建议，董事会决议提名孔健、张琰平及彭玲为第五届董事会执行董事候选人;马骉及孔双泉为第五届董事会非执行董事候选人;以及梁伟业、梁冶矢及侯爱军为第五届董事会独立非执行董事候选人(统称董事候选人)。除拟接替蒋先敏的候选人彭玲(其现担任公司监事兼首席技术官)外，各董事候选人均为现任董事。公司第四届监事会的任期将于2025年9月15日届满，而董事会及监事会均已决议提名现任监事孔茜为第五届监事会股东代表监事候选人。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1279775.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02480"],"gpt_icon":0},{"id":"2518571320","title":"绿竹生物-B03月11日主力净流入19万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2518571320","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518571320?lang=zh_cn&edition=full","pubTime":"2025-03-11 16:16","pubTimestamp":1741680990,"startTime":"0","endTime":"0","summary":"03月11日, 绿竹生物-B股价涨6.58%，报收24.30元，成交金额102万元，换手率0.02%，振幅6.14%，量比32.87。绿竹生物-B今日主力资金净流入19万元，上一交易日主力净流出0万元。该股近5个交易日上涨15.99%，主力资金累计净流入19万元；近20日主力资金累计净流入19万元，其中净流入天数为1日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311165944abf609cd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311165944abf609cd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02480","BK1161"],"gpt_icon":0},{"id":"2518175326","title":"绿竹生物-B盘中异动 快速上涨6.58%报24.300港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518175326","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518175326?lang=zh_cn&edition=full","pubTime":"2025-03-11 10:50","pubTimestamp":1741661433,"startTime":"0","endTime":"0","summary":"2025年03月11日早盘10时50分，绿竹生物-B股票出现异动，股价快速拉升6.58%。截至发稿，该股报24.300港元/股，成交量2600股，换手率0.00%，振幅5.70%。资金方面，该股资金流入6.27万港元，流出0港元。绿竹生物-B股票所在的生物技术行业中，整体涨幅为1.44%。其LZ901主要应用于预防年龄为50岁及以上成人水痘带状疱疹病毒引起的带状疱疹。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031110503398a345d0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031110503398a345d0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02480","BK1161"],"gpt_icon":0},{"id":"2518298889","title":"绿竹生物-B盘中异动 快速上涨5.86%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518298889","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518298889?lang=zh_cn&edition=full","pubTime":"2025-03-10 13:33","pubTimestamp":1741584786,"startTime":"0","endTime":"0","summary":"2025年03月10日下午盘13时33分，绿竹生物-B股票出现波动，股价急速上涨5.86%。绿竹生物-B股票所在的生物技术行业中，整体跌幅为2.67%。绿竹生物-B公司简介：北京绿竹生物技术股份有限公司是一家主要从事药物发现、研究及开发及商业化的中国公司。其LZ901主要应用于预防年龄为50岁及以上成人水痘带状疱疹病毒引起的带状疱疹。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310133306963fba33&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310133306963fba33&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02480","BK1161"],"gpt_icon":0},{"id":"2517215021","title":"绿竹生物-B盘中异动 急速下挫8.89%报20.500港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517215021","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517215021?lang=zh_cn&edition=full","pubTime":"2025-03-07 13:00","pubTimestamp":1741323604,"startTime":"0","endTime":"0","summary":"2025年03月07日下午盘13时00分，绿竹生物-B股票出现异动，股价快速下跌8.89%。截至发稿，该股报20.500港元/股，成交量600股，换手率0.00%，振幅8.67%。资金方面，该股资金流入4490港元，流出8200港元。绿竹生物-B股票所在的生物技术行业中，整体涨幅为0.37%。其临床阶段在研产品包括重组带状疱疹疫苗LZ901,以及抗体注射产品K3和K193。其LZ901主要应用于预防年龄为50岁及以上成人水痘带状疱疹病毒引起的带状疱疹。该公司在中国国内市场和海外市场开展业务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307130004abec66be&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307130004abec66be&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02480","BK1161"],"gpt_icon":0},{"id":"2513174798","title":"绿竹生物-B盘中异动 快速跳水7.80%报20.700港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513174798","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513174798?lang=zh_cn&edition=full","pubTime":"2025-02-24 10:00","pubTimestamp":1740362449,"startTime":"0","endTime":"0","summary":"2025年02月24日早盘10时00分，绿竹生物-B股票出现异动，股价快速跳水7.80%。截至发稿，该股报20.700港元/股，成交量400股，换手率0.00%，振幅0.00%。绿竹生物-B股票所在的生物技术行业中，整体跌幅为1.27%。其相关个股中，永泰生物-B、腾盛博药-B、昭衍新药涨幅较大，振幅较大的相关个股有永泰生物-B、腾盛博药-B、华昊中天医药-B，振幅分别为19.78%、17.72%、14.93%。其LZ901主要应用于预防年龄为50岁及以上成人水痘带状疱疹病毒引起的带状疱疹。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224100049989034b8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224100049989034b8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02480","BK1161"],"gpt_icon":0},{"id":"2512463766","title":"绿竹生物-B盘中异动 早盘大幅下跌7.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512463766","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512463766?lang=zh_cn&edition=full","pubTime":"2025-02-20 10:20","pubTimestamp":1740018023,"startTime":"0","endTime":"0","summary":"2025年02月20日早盘10时20分，绿竹生物-B股票出现异动，股价大幅下跌7.43%。绿竹生物-B股票所在的生物技术行业中，整体涨幅为0.42%。绿竹生物-B公司简介：北京绿竹生物技术股份有限公司是一家主要从事药物发现、研究及开发及商业化的中国公司。其临床阶段在研产品包括重组带状疱疹疫苗LZ901,以及抗体注射产品K3和K193。其LZ901主要应用于预防年龄为50岁及以上成人水痘带状疱疹病毒引起的带状疱疹。该公司在中国国内市场和海外市场开展业务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250220102023988bbab7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250220102023988bbab7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02480","BK1161"],"gpt_icon":0},{"id":"2511582766","title":"绿竹生物-B盘中异动 股价大跌9.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2511582766","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511582766?lang=zh_cn&edition=full","pubTime":"2025-02-14 14:44","pubTimestamp":1739515472,"startTime":"0","endTime":"0","summary":"2025年02月14日下午盘14时44分，绿竹生物-B股票出现异动，股价快速跳水9.55%。绿竹生物-B股票所在的生物技术行业中，整体涨幅为3.23%。其相关个股中，维亚生物、华领医药-B、晶泰控股-P涨幅较大，振幅较大的相关个股有维亚生物、方达控股、中国抗体-B，振幅分别为20.41%、18.24%、14.29%。其LZ901主要应用于预防年龄为50岁及以上成人水痘带状疱疹病毒引起的带状疱疹。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250214144432962299c1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250214144432962299c1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02480"],"gpt_icon":0},{"id":"2510580885","title":"又一款国产带状疱疹疫苗申报上市 中老年人的接种市场仍待撬开","url":"https://stock-news.laohu8.com/highlight/detail?id=2510580885","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510580885?lang=zh_cn&edition=full","pubTime":"2025-02-10 14:11","pubTimestamp":1739167895,"startTime":"0","endTime":"0","summary":"【又一款国产带状疱疹疫苗申报上市 中老年人的接种市场仍待撬开】2月9日晚间，绿竹生物（02480.HK）发布了其重组带状疱疹疫苗LZ901上市申请获得国家药监局受理消息。如顺利上市的话，这款疫苗将成为在国内上市的第三款带状疱疹疫苗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202502103314877975.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202502103314877975.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02480","BK1161"],"gpt_icon":0},{"id":"2510607276","title":"绿竹生物-B：LZ901生物制品许可申请获国家药监局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2510607276","media":"新浪网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510607276?lang=zh_cn&edition=full","pubTime":"2025-02-10 09:14","pubTimestamp":1739150070,"startTime":"0","endTime":"0","summary":"绿竹生物-B发布公告，于近日，集团的重组带状疱疹疫苗及核心产品LZ901的生物制品许可申请获得了中国国家药品监督管理局受理。LZ901是集团自主开发的重组带状疱疹疫苗，并且是集团的核心产品，旨在预防年龄为40岁及以上成人带状疱疹及带状疱疹引致的相关并发症的发生。LZ901于中国的III期临床试验已达到临床预设目标，并取得符合预期的临床结果。请读者仅作参考，并请自行承担全部责任。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210093226961d49e3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210093226961d49e3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02480"],"gpt_icon":0},{"id":"2510588045","title":"绿竹生物核心产品BLA许可申请获国家药监局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2510588045","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510588045?lang=zh_cn&edition=full","pubTime":"2025-02-09 20:21","pubTimestamp":1739103684,"startTime":"0","endTime":"0","summary":"财中社2月9日电绿竹生物-B（02480）发布公告，近日公司核心产品LZ901的生物制品许可申请（BLA）已获得中华人民共和国国家药监局受理。这一进展标志着公司在重组带状疱疹疫苗（CHO细胞）的研发过程中迈出了重要一步。LZ901旨在预防40岁及以上成人带状疱疹及其相关并发症，包括带状疱疹后遗神经痛，且在中国的III期临床试验中已达到预设目标并取得符合预期的临床结果。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202502093314223646.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02480","BK1161"],"gpt_icon":0},{"id":"2510010979","title":"【绿竹生物-B(02480.HK)：LZ901生物制品许可申请获国家药监局受理】绿竹生物-B(02480.HK)发布公告，于近日，集团的重组带状疱疹疫苗(CHO细胞)及核心产品LZ901的生物制品许可申请(BLA)获得了中国国家药品监督管理局受理。","url":"https://stock-news.laohu8.com/highlight/detail?id=2510010979","media":"金融界","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510010979?lang=zh_cn&edition=full","pubTime":"2025-02-09 18:50","pubTimestamp":1739098235,"startTime":"0","endTime":"0","summary":"绿竹生物-B(02480.HK)发布公告，于近日，集团的重组带状疱疹疫苗(CHO细胞)及核心产品LZ901的生物制品许可申请(BLA)获得了中国国家药品监督管理局受理。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/09185048038880.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["159646","02480","BK1161"],"gpt_icon":0},{"id":"2510108970","title":"绿竹生物-B(02480)：LZ901生物制品许可申请获国家药监局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2510108970","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510108970?lang=zh_cn&edition=full","pubTime":"2025-02-09 18:46","pubTimestamp":1739097976,"startTime":"0","endTime":"0","summary":"智通财经APP讯，绿竹生物-B(02480)发布公告，于近日，集团的重组带状疱疹疫苗(CHO细胞)及核心产品LZ901的生物制品许可申请(BLA)获得了中国国家药品监督管理局受理。LZ901是集团自主开发的重组带状疱疹疫苗(CHO细胞)，并且是集团的核心产品，旨在预防年龄为40岁及以上成人带状疱疹及带状疱疹引致的相关并发症的发生(包括带状疱疹后遗神经痛)。LZ901于中国的III期临床试验已达到临床预设目标，并取得符合预期的临床结果。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1247475.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02480","BK1161"],"gpt_icon":0}],"profile":{"websiteUrl":"http://luzhubiotech.com","stockEarnings":[{"period":"1week","weight":-0.1074},{"period":"1month","weight":-0.1308},{"period":"3month","weight":-0.1074},{"period":"6month","weight":0},{"period":"1year","weight":-0.216},{"period":"ytd","weight":-0.0588}],"compareEarnings":[{"period":"1week","weight":0.0297},{"period":"1month","weight":0.1316},{"period":"3month","weight":0.0777},{"period":"6month","weight":0.0988},{"period":"1year","weight":0.2436},{"period":"ytd","weight":0.1354}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"北京绿竹生物技术股份有限公司是一家主要从事疫苗及治疗性生物制剂的研究、开发及生产的中国公司。该公司还从事开发创新型人用疫苗及治疗性生物制剂，以预防及控制传染病以及治疗癌症及自身免疫性疾病。该公司的产品包括临床阶段的在研产品，以及临床前阶段的在研产品。核心产品LZ901，主要应用于预防年龄为50岁及以上成人水痘带状疱疹病毒引起的带状疱疹。该公司主要在国内市场开展其业务","exchange":"SEHK","name":"绿竹生物-B","nameEN":"LUZHU BIOTECH-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.4","shortVersion":"4.33.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"绿竹生物-B(02480)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供绿竹生物-B(02480)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"绿竹生物-B,02480,绿竹生物-B股票,绿竹生物-B股票老虎,绿竹生物-B股票老虎国际,绿竹生物-B行情,绿竹生物-B股票行情,绿竹生物-B股价,绿竹生物-B股市,绿竹生物-B股票价格,绿竹生物-B股票交易,绿竹生物-B股票购买,绿竹生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"绿竹生物-B(02480)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供绿竹生物-B(02480)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}